CStone Approved to Start China Trials of PD-L1 Candidate

CStone Pharma of Suzhou announced its PD-L1 monoclonal antibody, CS1001, was approved to begin clinical trials in China by the CFDA. One year ago, CStone raised $150 million in an A round from three China investors -- Oriza, Boyu and WuXi Healthcare. CStone said CS1001, which was approved after an eight-month review, is China's first fully human, full-length PD-L1 mAb to begin trials, although several PD-1 candidates have already started the clinical process. More details.... Share this with colleagues: // //